Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?
Patients with a %Sarc >10 have an increased risk of recurrence and mortality. These patients may benefit from a more stringent follow-up and %Sarc could represent an important criterion in the risk assessment for adjuvant therapy.
Authors
- Alan So (ORCID: https://orcid.org/0000-0001-6465-057X)
- Mustafa Soytaş (ORCID: https://orcid.org/0000-0002-3474-3510)
- Alice Dragomir
- Simon Tanguay (ORCID: https://orcid.org/0000-0001-6947-304X)
- Naveen S. Basappa (ORCID: https://orcid.org/0000-0002-3163-9902)
- Rodney H. Breau (ORCID: https://orcid.org/0000-0003-2344-9022)
- Aly‐Khan A. Lalani (ORCID: https://orcid.org/0000-0002-9907-9112)
- Ricardo Rendon (ORCID: https://orcid.org/0000-0002-4670-8384)
- Ghady Bou‐Nehme Sawaya
- Frédéric Pouliot (ORCID: https://orcid.org/0000-0002-6651-1079)
- Luke T. Lavallée (ORCID: https://orcid.org/0000-0001-9286-5965)
- Charles Hesswani (ORCID: https://orcid.org/0000-0002-7391-5004)
- Mario Tanguay (ORCID: https://orcid.org/0000-0001-5352-2871)
- Michael Bonert (ORCID: https://orcid.org/0000-0002-5049-0189)
- Bimal Bhindi (ORCID: https://orcid.org/0000-0002-6287-9837)
- Georg A. Bjarnason (ORCID: https://orcid.org/0000-0001-6903-5357)
- Lori Wood (ORCID: https://orcid.org/0000-0003-2405-0216)
- Jean‐Baptiste Lattouf (ORCID: https://orcid.org/0000-0002-8192-0508)
- Jasmir G. Nayak (ORCID: https://orcid.org/0000-0002-1360-7798)
- Antonio Finelli (ORCID: https://orcid.org/0000-0003-4032-6120)
- Rahul Bansal (ORCID: https://orcid.org/0000-0002-4449-5346)
- Lucas Dean
- Daniel Y.C. Heng
Institutions
- Alberta Health Services (CA)
- Dalhousie University (CA)
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- Juravinski Cancer Centre (CA)
- Queen Elizabeth II Health Sciences Centre (CA)
- Ottawa Hospital (CA)
- McGill University Health Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Université Laval (CA)
- University of Manitoba (CA)
- McGill University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1111/bju.16609
- Citations
- 4
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Pfizer
- Eisai
- Ipsen
- EMD Serono